Related Experiment Video

Updated: May 13, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice

Charalampos Kasmeridis1, Gregory Y Lip, Stavros Apostolakis

  • 1University of Birmingham Centre for Cardiovascular Sciences, Birmingham, UK.

Hospital Practice (1995)
|March 8, 2013
PubMed

Insights

New oral anticoagulants offer alternatives to warfarin for preventing blood clots in atrial fibrillation. This review assesses their safety, efficacy, and risk management for clinical use.

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiovascular Medicine
  • Hematology

Background:

  • Vitamin K antagonists (VKAs) were the sole oral anticoagulants for atrial fibrillation (AF) thromboembolism prevention for over 50 years.
  • Recent advancements include new oral anticoagulants (NOACs): direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban).

Purpose of the Study:

  • To provide a comprehensive assessment of the safety and efficacy of novel oral anticoagulants (NOACs).
  • To analyze the balance between thromboembolic and bleeding risks associated with NOACs.
  • To discuss the clinical implications and utilization of risk estimation tools for NOACs in practice.

Main Methods:

  • Review of phase 3 clinical trial data for dabigatran, rivaroxaban, and apixaban.
  • Analysis of safety and efficacy endpoints, focusing on thromboembolic and hemorrhagic events.
  • Evaluation of risk stratification tools for guiding NOAC therapy.

Main Results:

  • NOACs have demonstrated comparable or improved efficacy in preventing thromboembolism compared to VKAs.
  • The safety profile of NOACs, particularly regarding major bleeding, is a key consideration.
  • Apixaban, a direct factor Xa inhibitor, received FDA approval in December 2012.

Conclusions:

  • NOACs represent a significant advancement in oral anticoagulation for AF patients.
  • Careful consideration of the benefit-risk profile, including bleeding and thromboembolic risks, is crucial for optimal patient management.
  • Risk assessment tools are important for the appropriate selection and utilization of NOACs in clinical practice.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...